A Phase 1 interventional study of Pembrolizumab Dose C and Pembrolizumab Dose A in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Melanoma by Merck & Co., Inc — 1 open to participants now, 6 under way, 3 of them phase 3. Melanoma · Merck & Co., Inc.
Among the 42 studies in Melanoma by Merck & Co., Inc, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2018, is one of 13 in phase 1, and was the 28th registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →1 of the 42 studies in Melanoma by Merck & Co., Inc is open now, in 9 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Brazil, France and 6 more countries
Ages 6 mo–17 yrs
By country, each count listing its studies:
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 17 · Phase 3 9 · Phase 4 1
First in 1996; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 131 across the 39 interventional studies, 219 across the 2 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 42 studies in Melanoma by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the pharmacokinetic (PK) profile of pembrolizumab (MK-3475) following single subcutaneous (SC) injection of pembrolizumab Dose A versus pembrolizumab Dose C in adults with advanced melanoma. Additionally, the safety and tolerability of pembrolizumab SC injections will be assessed. And, finally, the efficacy of pembrolizumab intravenous (IV) infusion administration will be assessed.
This study consists of two cohorts. Participants in Cohort A are randomized to one of six treatment sequences which will include 2 cycles of pembrolizumab administered via subcutaneous injection and 1 cycle of intravenous (IV) infusion, followed by up to 32 cycles (up to \~2 years) of pembrolizumab administered via IV infusion (each cycle is 21 days). Participants in Cohort B will receive pembrolizumab via IV infusion on Day 1 of each 21-day cycle for up to 18 cycles, up to \~ 2 years. Each cycle is 42 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 165 mg/mL subcutaneously (SC); Cycle 2 Day 1: pembrolizumab 200 mg intravenously (IV); Cycle 3 Day 1: pembrolizumab 130 mg/mL SC; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.
Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B
Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 165 mg/mL SC; Cycle 2 Day 1: pembrolizumab 130 mg/mL SC; Cycle 3 Day 1: pembrolizumab 200 mg IV; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.
Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B
Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 130 mg/mL SC; Cycle 2 Day 1: pembrolizumab 165 mg/mL SC; Cycle 3 Day 1: pembrolizumab 200 mg IV; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.
Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B
Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 200 mg SC; Cycle 2 Day 1: pembrolizumab 200 mg IV; Cycle 3 Day 1: pembrolizumab 130 mg/mL SC; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab Dose 200 mg IV.
Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B
Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 200 mg IV; Cycle 2 Day 1: pembrolizumab 130 mg/mL SC; Cycle 3 Day 1: pembrolizumab 165 mg/mL SC: Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.
Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B
Participants receive a single dose of pembrolizumab in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembrolizumab 200 mg IV; Cycle 2 Day 1: pembrolizumab 165 mg/mL SC; Cycle 3 Day 1: pembrolizumab 130 mg/mL SC; Cycle 4 Day 1 and every cycle thereafter, up to a total of 35 cycles (up to approximately 2 years), Day 1: pembrolizumab 200 mg IV.
Biological: Pembrolizumab Dose C · Biological: Pembrolizumab Dose A · Biological: Pembrolizumab Dose B
Participants receive a single dose of pembrolizumab 400 mg IV on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for up to 18 cycles (up to approximately 2 years).
Biological: Pembrolizumab Dose D
165 mg/mL administered to a final dose of 285 mg via subcutaneous injection
Also known as: KEYTRUDA®, MK-3475
130 mg/mL administered to a final dose of 285 mg via subcutaneous injection
Also known as: KEYTRUDA®, MK-3475
200 mg administered via intravenous infusion
Also known as: KEYTRUDA®, MK-3475
400 mg administered via intravenous infusion
Also known as: KEYTRUDA®, MK-3475
This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Area Under the Concentration-Time Curve (AUC) of Pembrolizumab - Cohort A
AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points and a pharmacokinetic (PK) model based on historical intravenous pembrolizumab PK data were used for the determination of the AUC of pembrolizumab. Geometric least-square mean (GM) and 95% confidence intervals were derived from mixed-effects model performed on natural log-transformed values. Data were reported by treatment received.
Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Maximum Plasma Concentration (Cmax) of Pembrolizumab - Cohort A
Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points and a PK model based on historical intravenous pembrolizumab PK data were used for the determination of the AUC of pembrolizumab. GM and 95% confidence intervals were derived from mixed-effects model performed on natural log-transformed values. Data were reported by treatment received.
Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Bioavailability (F) of Pembrolizumab - Cohort A
Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the F of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.
Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Absorption Rate Constant (Ka) of Pembrolizumab - Cohort A
Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the Ka of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported. Participants in Cohort B weren't analyzed, per protocol.
Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Time of Maximum Plasma Concentration (Tmax) of Pembrolizumab - Cohort A
Blood samples were collected at designated time points for the determination of the Tmax of pembrolizumab.
Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Clearance (CL) of Pembrolizumab - Cohort A
Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the CL of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.
Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Central Volume of Distribution (Vc) of Pembrolizumab - Cohort A
Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the Vc of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.
Time frame: Cycles 1-3: Day 1 Predose and Days 2, 5, 10 and 15; Cycle 4: Day 1 Predose. Samples were also collected after IV infusion on Cycles 1-3: Day 1 ~0.5 hours after infusion and after SC injection on Days 3, 4, 6, and 7. Each cycle was 21 days.
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Cohort B
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). Responses were based upon blinded independent central review (BICR) per RECIST 1.1. ORR was reported for participants in Cohort B.
Time frame: Up to approximately 54 months
Number of Participants Positive for Pembrolizumab Anti-Drug Antibody (ADA) Formation - Cohort A
Blood samples were collected at designated time points for the determination of the presence or absence of pembrolizumab anti-drug antibodies. The number of participants who develop anti-pembrolizumab antibodies were assessed in Cycles 1 through Cycle 4. Per ADA immunogenicity analysis report, data from participants in Cohort A were reported combined across treatment cycles 1-4.
Time frame: Cycles 1-4 Day 1: Predose. Each cycle is 21 days. (Up to approximately 64 days)
Number of Participants Who Experienced One or More Adverse Event (AEs) - Cohort A
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced one or more AEs in Cohort A was reported. Per protocol, data were reported by treatment received and AEs from Cycles 4-35 were reported separately.
Time frame: Up to approximately 27 months
Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort A
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued due to an AE in Cohort A were reported. Per protocol, data were reported by treatment received and data from Cycles 4-35 were reported separately.
Time frame: Up to approximately 23 months
Number of Participants With One or More Injection Site Signs and Symptoms After Subcutaneous Pembrolizumab Injection in Cycles 1-3 - Cohort A
Participants completed the Injection Site Signs and Symptoms Questionnaire, within 60 minutes after each pembrolizumab SC injection during Cycles 1-3. Participants rated any pain, itching, swelling and redness they experienced at the pembrolizumab SC injection site from "None" to "Severe". The number of participants who experienced an injection site sign or symptom was reported.
Time frame: Cycles 1-3 Day 1: Up to 60 minutes postdose. Each cycle is 21 days. (Up to approximately 43 days)
Duration of Response (DOR) Per RECIST 1.1 - Cohort B
For participants who demonstrated a CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR was calculated for RECIST 1.1 based on BICR. DOR for Cohort B was reported.
Time frame: Up to approximately 54 months
Progression-free Survival (PFS) Per to RECIST v1.1 Modified to Follow a Maximum of 10 Target Lesions and a Maximum of 5 Target Lesions Per Organ - Cohort B
PFS was defined as the time from the first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Although RECIST 1.1 was modified to allow for a maximum of 10 target lesions in total and 5 per organ. Per protocol, PFS as assessed by BICR for participants in Cohort B was reported.
Time frame: Up to approximately 54 months
Overall Survival (OS) - Cohort B
OS was defined as the time from the first dose of study treatment to death due to any cause. Per protocol, OS for participants in Cohort B was reported.
Time frame: Up to approximately 54 months
Early Cycle AUC of Pembrolizumab - Cohort B
AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points for the determination of the pembrolizumab AUC in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. A cycle was 42 days.
Time frame: Cycle 1: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 2: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Steady State AUC of Pembrolizumab - Cohort B
AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points for the determination of the pembrolizumab AUC in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last samples (trough concentration) of Cycle 4. Each cycle was 42 days.
Time frame: Cycle 4: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 5: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Early Cycle Cmax of Pembrolizumab - Cohort B
Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmax in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. Each cycle was 42 days.
Time frame: Cycle 1: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 2: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Steady State Cmax of Pembrolizumab - Cohort B
Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmax in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last sample (trough concentration) of Cycle 4. Each cycle was 42 days.
Time frame: Cycle 4: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 5: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Early Cycle Minimum Plasma Concentration (Cmin) of Pembrolizumab - Cohort B
Cmin was defined as the minimum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmin in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. Each cycle was 42 days.
Time frame: Cycle 1: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 2: Predose. A Cycle was 42 days. (Up to approximately 6 weeks)
Steady State Cmin of Pembrolizumab - Cohort B
Cmin was defined as the minimum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmin in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last sample (trough concentration) of Cycle 4. Each cycle was 42 days.
Time frame: Cycle 4: Day 1 Predose and ~5 minutes post infusion and Day 22; Cycle 5: Predose. Each Cycle was 42 days. (Up to approximately 6 weeks)
Number of Participants Who Experienced One or More AEs - Cohort B
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced one or more AEs in Cohort B was reported.
Time frame: Up to approximately 54 months
Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort B
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued due to an AE in Cohort B were reported.
Time frame: Up to approximately 26 months
| Milestone | Cohort A Pembrolizumab Treatment Sequence 1 | Cohort A Pembrolizumab Treatment Sequence 2 | Cohort A Pembrolizumab Treatment Sequence 3 | Cohort A Pembrolizumab Treatment Sequence 4 | Cohort A Pembrolizumab Treatment Sequence 5 | Cohort A Pembrolizumab Treatment Sequence 6 | Cohort B Pembrolizumab 400 mg IV |
|---|---|---|---|---|---|---|---|
| Started | 7 | 6 | 6 | 6 | 5 | 7 | 101 |
| Treated | 7 | 6 | 6 | 5 | 5 | 7 | 101 |
| Completed | 6 | 6 | 6 | 4 | 5 | 7 | 51 |
| Not completed | 1 | 0 | 0 | 2 | 0 | 0 | 50 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Screen failure | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 45 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Milestone | Cohort A Pembrolizumab Treatment Sequence 1 | Cohort A Pembrolizumab Treatment Sequence 2 | Cohort A Pembrolizumab Treatment Sequence 3 | Cohort A Pembrolizumab Treatment Sequence 4 | Cohort A Pembrolizumab Treatment Sequence 5 | Cohort A Pembrolizumab Treatment Sequence 6 | Cohort B Pembrolizumab 400 mg IV |
|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 4 | 5 | 7 | 0 |
| Treated | 6 | 6 | 6 | 4 | 4 | 7 | 0 |
| Completed | 6 | 6 | 6 | 4 | 5 | 6 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Cohort A Pembrolizumab Treatment Sequence 1 | Cohort A Pembrolizumab Treatment Sequence 2 | Cohort A Pembrolizumab Treatment Sequence 3 | Cohort A Pembrolizumab Treatment Sequence 4 | Cohort A Pembrolizumab Treatment Sequence 5 | Cohort A Pembrolizumab Treatment Sequence 6 | Cohort B Pembrolizumab 400 mg IV |
|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 4 | 5 | 6 | 0 |
| Treated | 6 | 6 | 6 | 4 | 4 | 6 | 0 |
| Completed | 6 | 5 | 6 | 4 | 4 | 6 | 0 |
| Not completed | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Cohort A Pembrolizumab Treatment Sequence 1 | Cohort A Pembrolizumab Treatment Sequence 2 | Cohort A Pembrolizumab Treatment Sequence 3 | Cohort A Pembrolizumab Treatment Sequence 4 | Cohort A Pembrolizumab Treatment Sequence 5 | Cohort A Pembrolizumab Treatment Sequence 6 | Cohort B Pembrolizumab 400 mg IV |
|---|---|---|---|---|---|---|---|
| Started | 6 | 5 | 6 | 4 | 4 | 6 | 0 |
| Treated | 6 | 5 | 6 | 4 | 3 | 6 | 0 |
| Completed | 3 | 1 | 2 | 2 | 3 | 6 | 0 |
| Not completed | 3 | 4 | 4 | 2 | 1 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 2 | 2 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points and a pharmacokinetic (PK) model based on historical intravenous pembrolizumab PK data were used for the determination of the AUC of pembrolizumab. Geometric least-square mean (GM) and 95% confidence intervals were derived from mixed-effects model performed on natural log-transformed values. Data were reported by treatment received.
| mg*day/L | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV |
|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) of Pembrolizumab - Cohort A | 507 (440 to 585) | 480 (418 to 551) | 695 (631 to 766) |
Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points and a PK model based on historical intravenous pembrolizumab PK data were used for the determination of the AUC of pembrolizumab. GM and 95% confidence intervals were derived from mixed-effects model performed on natural log-transformed values. Data were reported by treatment received.
| mg/L | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Pembrolizumab - Cohort A | 28.6 (24.7 to 33.1) | 26.8 (23.2 to 30.9) | 71.3 (65.6 to 77.5) |
Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the F of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.
| Percent | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV | Combined Cohort A |
|---|---|---|---|---|
| Bioavailability (F) of Pembrolizumab - Cohort A | — | — | — | 66 (58 to 74) |
Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the Ka of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported. Participants in Cohort B weren't analyzed, per protocol.
| 1/day | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV | Combined Cohort A |
|---|---|---|---|---|
| Absorption Rate Constant (Ka) of Pembrolizumab - Cohort A | — | — | — | 0.191 ± 13.1 |
Blood samples were collected at designated time points for the determination of the Tmax of pembrolizumab.
| Days | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3) |
|---|---|---|---|
| Time of Maximum Plasma Concentration (Tmax) of Pembrolizumab - Cohort A | 6.55 (3.70 to 21.00) | 8.35 (3.00 to 21.00) | 0.02 (0.02 to 0.02) |
Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the CL of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.
| Liters/day | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV | Combined Cohort A |
|---|---|---|---|---|
| Clearance (CL) of Pembrolizumab - Cohort A | — | — | — | 0.25 ± 6.28 |
Blood samples were collected at designated time points and a population PK model based on historical intravenous pembrolizumab PK data was used for the determination of the Vc of pembrolizumab. Per protocol, an integrated population PK analysis was performed and combined data for Cohort A was reported.
| Liters | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV | Combined Cohort A |
|---|---|---|---|---|
| Central Volume of Distribution (Vc) of Pembrolizumab - Cohort A | — | — | — | 3.39 ± 5.68 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). Responses were based upon blinded independent central review (BICR) per RECIST 1.1. ORR was reported for participants in Cohort B.
| Percentage of Participants | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Cohort B | 53.5 (43.3 to 63.5) |
Blood samples were collected at designated time points for the determination of the presence or absence of pembrolizumab anti-drug antibodies. The number of participants who develop anti-pembrolizumab antibodies were assessed in Cycles 1 through Cycle 4. Per ADA immunogenicity analysis report, data from participants in Cohort A were reported combined across treatment cycles 1-4.
| Participants | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV | Combined Cohort A |
|---|---|---|---|---|
| Number of Participants Positive for Pembrolizumab Anti-Drug Antibody (ADA) Formation - Cohort A | — | — | — | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced one or more AEs in Cohort A was reported. Per protocol, data were reported by treatment received and AEs from Cycles 4-35 were reported separately.
| Participants | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3) | Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35) |
|---|---|---|---|---|
| Number of Participants Who Experienced One or More Adverse Event (AEs) - Cohort A | 18 | 18 | 14 | 29 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued due to an AE in Cohort A were reported. Per protocol, data were reported by treatment received and data from Cycles 4-35 were reported separately.
| Participants | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3) | Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35) |
|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort A | 1 | 0 | 1 | 5 |
Participants completed the Injection Site Signs and Symptoms Questionnaire, within 60 minutes after each pembrolizumab SC injection during Cycles 1-3. Participants rated any pain, itching, swelling and redness they experienced at the pembrolizumab SC injection site from "None" to "Severe". The number of participants who experienced an injection site sign or symptom was reported.
| Participants | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3) |
|---|---|---|---|
| Number of Participants With One or More Injection Site Signs and Symptoms After Subcutaneous Pembrolizumab Injection in Cycles 1-3 - Cohort A | 3 | 2 | — |
For participants who demonstrated a CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR was calculated for RECIST 1.1 based on BICR. DOR for Cohort B was reported.
| Months | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Duration of Response (DOR) Per RECIST 1.1 - Cohort B | NA (NA to NA) |
PFS was defined as the time from the first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Although RECIST 1.1 was modified to allow for a maximum of 10 target lesions in total and 5 per organ. Per protocol, PFS as assessed by BICR for participants in Cohort B was reported.
| Months | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Progression-free Survival (PFS) Per to RECIST v1.1 Modified to Follow a Maximum of 10 Target Lesions and a Maximum of 5 Target Lesions Per Organ - Cohort B | 13.8 (5.3 to 41.4) |
OS was defined as the time from the first dose of study treatment to death due to any cause. Per protocol, OS for participants in Cohort B was reported.
| Months | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Overall Survival (OS) - Cohort B | NA (27.1 to NA) |
AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points for the determination of the pembrolizumab AUC in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. A cycle was 42 days.
| μg/ml | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Early Cycle AUC of Pembrolizumab - Cohort B | NA (NA to NA) |
AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of plasma drug concentration and time. Blood samples were collected at designated time points for the determination of the pembrolizumab AUC in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last samples (trough concentration) of Cycle 4. Each cycle was 42 days.
| μg/ml | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Steady State AUC of Pembrolizumab - Cohort B | NA (NA to NA) |
Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmax in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. Each cycle was 42 days.
| μg/ml | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Early Cycle Cmax of Pembrolizumab - Cohort B | 127.0 (121.3 to 132.7) |
Cmax was defined as the maximum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmax in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last sample (trough concentration) of Cycle 4. Each cycle was 42 days.
| μg/ml | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Steady State Cmax of Pembrolizumab - Cohort B | 150.0 (141.9 to 158.3) |
Cmin was defined as the minimum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmin in participants in Cohort B during Cycle 1 (early cycle). Blood samples were also collected predose on Day 1 of Cycle 2 just prior to the next dose as the last sample (trough concentration) of Cycle 1. Each cycle was 42 days.
| μg/ml | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Early Cycle Minimum Plasma Concentration (Cmin) of Pembrolizumab - Cohort B | 15.1 (13.5 to 16.9) |
Cmin was defined as the minimum concentration of pembrolizumab observed in plasma following a single dose. Blood samples were collected at designated time points for the determination of the pembrolizumab Cmin in participants in Cohort B during Cycle 4 (steady state). Blood samples were also collected predose on Day 1 of Cycle 5 just prior to the next dose as the last sample (trough concentration) of Cycle 4. Each cycle was 42 days.
| μg/ml | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Steady State Cmin of Pembrolizumab - Cohort B | 24.0 (20.6 to 27.9) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced one or more AEs in Cohort B was reported.
| Participants | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Number of Participants Who Experienced One or More AEs - Cohort B | 101 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued due to an AE in Cohort B were reported.
| Participants | Cohort B Pembrolizumab 400 mg IV |
|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE - Cohort B | 8 |
Collected over Up to approximately 54 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A Pembrolizumab 130 mg/mL SC | 1/34 (2.9%) | 1/33 (3%) | 15/33 (45.5%) |
| Cohort A Pembrolizumab 165 mg/mL SC | 3/35 (8.6%) | 2/34 (5.9%) | 15/34 (44.1%) |
| Cohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3) | 1/35 (2.9%) | 2/34 (5.9%) | 8/34 (23.5%) |
| Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35) | 4/31 (12.9%) | 9/30 (30%) | 27/30 (90%) |
| Cohort B Pembrolizumab 400 mg IV | 45/101 (44.6%) | 31/101 (30.7%) | 93/101 (92.1%) |
| Event | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3) | Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35) | Cohort B Pembrolizumab 400 mg IV |
|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/33 | 0/34 | 0/34 | 3/30 | 1/101 |
| PneumoniaInfections and infestations | 0/33 | 0/34 | 0/34 | 0/30 | 4/101 |
| AnaemiaBlood and lymphatic system disorders | 0/33 | 1/34 | 0/34 | 1/30 | 2/101 |
| Adrenal insufficiencyEndocrine disorders | 0/33 | 0/34 | 0/34 | 1/30 | 0/101 |
| Intestinal obstructionGastrointestinal disorders | 1/33 | 0/34 | 0/34 | 1/30 | 0/101 |
| Hepatitis acuteHepatobiliary disorders | 0/33 | 0/34 | 0/34 | 1/30 | 0/101 |
| InfectionInfections and infestations | 0/33 | 0/34 | 0/34 | 1/30 | 0/101 |
| Tumour compressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/33 | 0/34 | 0/34 | 1/30 | 0/101 |
| SeizureNervous system disorders | 0/33 | 0/34 | 0/34 | 1/30 | 0/101 |
| Pleural disorderRespiratory, thoracic and mediastinal disorders | 0/33 | 0/34 | 0/34 | 1/30 | 0/101 |
| Event | Cohort A Pembrolizumab 130 mg/mL SC | Cohort A Pembrolizumab 165 mg/mL SC | Cohort A Pembrolizumab 200 mg IV (Cycle 1 - Cycle 3) | Cohort A Pembrolizumab 200 mg IV (Cycle 4 - Cycle 35) | Cohort B Pembrolizumab 400 mg IV |
|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/33 | 2/34 | 0/34 | 7/30 | 32/101 |
| FatigueGeneral disorders | 0/33 | 1/34 | 0/34 | 7/30 | 29/101 |
| Alanine aminotransferase increasedInvestigations | 0/33 | 0/34 | 1/34 | 8/30 | 14/101 |
| VitiligoSkin and subcutaneous tissue disorders | 0/33 | 0/34 | 0/34 | 8/30 | 25/101 |
| RashSkin and subcutaneous tissue disorders | 2/33 | 0/34 | 1/34 | 5/30 | 22/101 |
| NauseaGastrointestinal disorders | 1/33 | 2/34 | 0/34 | 6/30 | 17/101 |
| PruritusSkin and subcutaneous tissue disorders | 1/33 | 1/34 | 1/34 | 6/30 | 20/101 |
| DiarrhoeaGastrointestinal disorders | 2/33 | 1/34 | 0/34 | 5/30 | 20/101 |
| AnaemiaBlood and lymphatic system disorders | 0/33 | 1/34 | 0/34 | 0/30 | 16/101 |
| Weight decreasedInvestigations | 2/33 | 0/34 | 0/34 | 2/30 | 14/101 |
| Age, Continuous(Years) | Cohort A Pembrolizumab Treatment Sequence 1 | Cohort A Pembrolizumab Treatment Sequence 2 | Cohort A Pembrolizumab Treatment Sequence 3 | Cohort A Pembrolizumab Treatment Sequence 4 | Cohort A Pembrolizumab Treatment Sequence 5 | Cohort A Pembrolizumab Treatment Sequence 6 | Cohort B Pembrolizumab 400 mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 60.9 ± 14.9 | 54.0 ± 20.1 | 58.2 ± 12.4 | 49.8 ± 16.7 | 59.8 ± 18.0 | 63.0 ± 22.5 | 62.1 ± 13.9 | 60.9 ± 14.9 |
| Sex: Female, Male(Participants) | Cohort A Pembrolizumab Treatment Sequence 1 | Cohort A Pembrolizumab Treatment Sequence 2 | Cohort A Pembrolizumab Treatment Sequence 3 | Cohort A Pembrolizumab Treatment Sequence 4 | Cohort A Pembrolizumab Treatment Sequence 5 | Cohort A Pembrolizumab Treatment Sequence 6 | Cohort B Pembrolizumab 400 mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 3 | 1 | 2 | 36 | 45 |
| Male | 6 | 5 | 5 | 3 | 4 | 5 | 65 | 93 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A Pembrolizumab Treatment Sequence 1 | Cohort A Pembrolizumab Treatment Sequence 2 | Cohort A Pembrolizumab Treatment Sequence 3 | Cohort A Pembrolizumab Treatment Sequence 4 | Cohort A Pembrolizumab Treatment Sequence 5 | Cohort A Pembrolizumab Treatment Sequence 6 | Cohort B Pembrolizumab 400 mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 4 | 6 | 4 | 3 | 5 | 93 | 120 |
| Unknown or Not Reported | 2 | 2 | 0 | 2 | 2 | 2 | 8 | 18 |
| Race (NIH/OMB)(Participants) | Cohort A Pembrolizumab Treatment Sequence 1 | Cohort A Pembrolizumab Treatment Sequence 2 | Cohort A Pembrolizumab Treatment Sequence 3 | Cohort A Pembrolizumab Treatment Sequence 4 | Cohort A Pembrolizumab Treatment Sequence 5 | Cohort A Pembrolizumab Treatment Sequence 6 | Cohort B Pembrolizumab 400 mg IV | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 |
| White | 7 | 6 | 6 | 6 | 5 | 7 | 87 | 124 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2018 to primary completion in Dec 2023, 60 months.
Results were first posted in Feb 2025, 1 year 2 months after primary completion.
Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 60 months is above that.
Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pembrolizumab